Drug trials

Small and medium-size contract research organisations (CROs) have huge potential. For the last few decades, pharmaceutical companies have increasingly chosen to use medium-size contract research organisations (CROs), or smaller organisations, rather than the larger organisations, due to their enhanced responsiveness and flexibility, that provides good geographic coverage, a broad therapeutic…

Photo

Defying physics

Dr Robert Krieg, Director of MR Molecular Imaging at Siemens Medical Solutions, described, in an interview with Daniela Zimmermann of European Hospital, the limitations of physics and the potential clinical benefits of hybrid technology - and a hitherto hush-hush MRI-PET project

33 show more articles
Subscribe to Newsletter